S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
For locally advanced adenocarcinoma of esophagogastric junction(AEG) (cT3-4aN+M0),
neoadjuvant chemotherapy was improved to downstage T and N stage, increase the resectability
of tumor, and finally improve the long-term survival. Combination of perioperative PD-1
antibody and chemotherapy for locally advanced AEG could be a novel therapy to increase
response rate and resectability and reduce recurrence rate. Sintilimab in this study is an
anti-PD-1 monoclonal antibody for injection which has been approved for several malignant
tumors. This study is a multi-center, open-label, randomized phase II clinical trial to
evaluate tolerability, safety and efficacy of sintilimab in combination with perioperative
chemotherapy in locally advanced AEG.